← Back to Clinical Trials
Recruiting NCT05638191

NCT05638191 Nerve Transfer Surgery to Restore Upper-limb Function After Cervical Spinal Cord Injury

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05638191
Status Recruiting
Phase
Sponsor University of British Columbia
Condition Spinal Cord Injury
Study Type OBSERVATIONAL
Enrollment 40 participants
Start Date 2021-06-03
Primary Completion 2028-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 70 Years
Study Type OBSERVATIONAL
Interventions
Nerve transfer surgery

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 40 participants in total. It began in 2021-06-03 with a primary completion date of 2028-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this prospective, open-label cohort study is to assess functional outcomes in individuals with cervical spinal cord injury who have undergone nerve transfer surgery to restore upper limb function. The main questions it aims to answer are: * Does nerve transfer improve hand function in individuals with cervical spinal cord injury? * What factors are associated with functional improvement following nerve transfer? Researchers will compare functional outcomes at 24 months post-surgery to 1) baseline outcomes and 2) individuals with cervical spinal cord injury who did not undergo nerve transfer. Participants who have received nerve transfer surgery as part of their regular medical care will complete functional hand tests, electrodiagnostic assessments, and questionnaires on independence and mood every 3 months for 24 months after surgery.

Eligibility Criteria

Inclusion Criteria: * Traumatic, motor-complete cervical SCI (AIS A or B) * Male or female, ages 18-70 * Consent and plan to undergo nerve transfer to restore grasp function in at least one limb * Motor grade 4-5 at C5 * Motor grade 0-1 at C8/T1 * Injury duration within 6 months at the time of surgery * English-speaking and cognitively intact * Able to provide informed written consent * Able to attend and comply with the testing protocols Exclusion Criteria: * Inability or unwillingness to participate in post-operative rehabilitation (in person or virtual) * Secondary complication of SCI (e.g., intractable neuropathic pain, edema, contracture) or major medical comorbidity (e.g., traumatic brain injury) that would independently influence response to surgery or ability to participate in rehabilitation

Contact & Investigator

Central Contact

Michael Berger, MD, PhD

✉ michael.berger@vch.ca

📞 778-990-7615

Principal Investigator

Michael Berger, MD, PHD

PRINCIPAL INVESTIGATOR

University of British Columbia

Frequently Asked Questions

Who can join the NCT05638191 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Spinal Cord Injury. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05638191 currently recruiting?

Yes, NCT05638191 is actively recruiting participants. Contact the research team at michael.berger@vch.ca for enrollment information.

Where is the NCT05638191 trial being conducted?

This trial is being conducted at Vancouver, Canada, Halifax, Canada, Kingston, Canada, Toronto, Canada.

Who is sponsoring the NCT05638191 clinical trial?

NCT05638191 is sponsored by University of British Columbia. The principal investigator is Michael Berger, MD, PHD at University of British Columbia. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology